These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35732409)

  • 61. Primary anaplastic large cell lymphoma in the dura of the brain: case report and prediction of a favorable prognosis.
    Kim MK; Cho CH; Sung WJ; Ryoo HM; Lee HJ; Youn SW; Park KK
    Int J Clin Exp Pathol; 2013; 6(8):1643-51. PubMed ID: 23923083
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Successful long-term control of recurrent primary central nervous system anaplastic large cell lymphoma after autologous hematopoietic stem cell transplantation with concurrent whole brain and spinal cord radiotherapy].
    Hiroshima Y; Kaiume H; Kirihara T; Takeda W; Kurihara T; Sato K; Shimizu I; Ueki T; Sumi M; Ueno M; Ichikawa N; Asano N; Watanabe M; Kobayashi H
    Rinsho Ketsueki; 2015 Dec; 56(12):2477-82. PubMed ID: 26725359
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma.
    Fukano R; Mori T; Fujita N; Kobayashi R; Mitsui T; Kato K; Suzuki R; Suzumiya J; Fukuda T; Shindo M; Maseki N; Shimoyama T; Okada K; Inoue M; Inagaki J; Hashii Y; Sato A; Tabuchi K
    Int J Hematol; 2019 Dec; 110(6):723-728. PubMed ID: 31620968
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center.
    Gibb A; Jones C; Bloor A; Kulkarni S; Illidge T; Linton K; Radford J
    Haematologica; 2013 Apr; 98(4):611-4. PubMed ID: 23065511
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma-Response.
    Knörr F; Woessmann W
    Br J Haematol; 2023 Jan; 200(1):107-108. PubMed ID: 36259567
    [No Abstract]   [Full Text] [Related]  

  • 67. Brentuximab vedotin in anaplastic large cell lymphoma.
    Skarbnik AP; Smith MR
    Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
    Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
    Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Role of ALK Inhibitors in Anaplastic Large Cell Lymphoma-Experience from an Indian Center.
    Indhuja MV; Kesana S; Mehra N; Karunakaran P; Rajan AK; Radhakrishnan V; Jayachandran PK
    South Asian J Cancer; 2024 Apr; 13(2):121-125. PubMed ID: 38919655
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.
    Garciaz S; Loschi M; De Masson A; Biard L; Mercier M; Tomowiak C; Delage J; Labussiere-Wallet H; Sibon D; Cassuto O; Borel C; Cornillon J; Nimubona S; Charbonnier A; Brice P; Socié G; Bouabdallah R; de Latour RP; de Fontbrune FS
    Leuk Lymphoma; 2019 Nov; 60(11):2802-2805. PubMed ID: 31014144
    [No Abstract]   [Full Text] [Related]  

  • 71. Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning for a child with recurrent anaplastic large cell lymphoma.
    Ohta H; Kusuki S; Yoshida H; Sato E; Hashii Y; Ozono K
    Int J Hematol; 2010 Jul; 92(1):190-3. PubMed ID: 20549579
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
    Rogers AM; Brammer JE
    Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
    Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
    Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT.
    Domingo-Domènech E; Boumendil A; Climent F; Sengeloev H; Wahlin B; Wattad W; Arat M; Finel H; Schapp N; Ganser A; Yeshurun M; Pavone V; Snowden J; Finke J; Montoto S; Sureda A; Dreger P;
    Bone Marrow Transplant; 2020 Apr; 55(4):796-803. PubMed ID: 31695174
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Allogeneic haematopoietic stem cell transplantation as a salvage strategy for relapsed or refractory nasal NK/T-cell lymphoma.
    Li M; Gao C; Li H; Wang Z; Cao Y; Huang W; Li X; Wang S; Yu L; Da W
    Med Oncol; 2011 Sep; 28(3):840-5. PubMed ID: 20414818
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [TBL] [Abstract][Full Text] [Related]  

  • 78. ALK-positive anaplastic large cell lymphoma in adults.
    Gromowsky MJ; D'Angelo CR; Lunning MA; Armitage JO
    Fac Rev; 2023; 12():21. PubMed ID: 37655119
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
    Shustov A
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan.
    Fukano R; Mori T; Kobayashi R; Mitsui T; Fujita N; Iwasaki F; Suzumiya J; Chin M; Goto H; Takahashi Y; Hara J; Park YD; Inoue M; Koga Y; Inagaki J; Sakamaki H; Adachi S; Kawa K; Kato K; Suzuki R
    Br J Haematol; 2015 Feb; 168(4):557-63. PubMed ID: 25312752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.